Progress in Analysis of Tau Protein

LinYu, Li; Wang, Xiaoying

doi:10.1016/s1872-2040(20)60024-x

Cited by 7 publications

(4 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The detection limit (LOD) was 0.028 pM (calculation details available in the Supporting Information), far below the BD-tau level in plasma. Furthermore, the sensitivity of our developed MoSe 2 SERS platform outperformed other methods such as electrochemical method and enzyme linked immunosorbent assay (ELISA) . Subsequently, Raman signals were scanned through a computer-controlled x – y translation stage to obtain a 2D Raman-mapped image based on the peak intensity ratio I 1618 / I 232 corresponding to each concentration.…”

Section: Resultsmentioning

confidence: 99%

“…Furthermore, the sensitivity of our developed MoSe 2 SERS platform outperformed other methods such as electrochemical method 9 and enzyme linked immunosorbent assay (ELISA). 25 Subsequently, Raman signals were scanned through a computer-controlled x−y translation stage to obtain a 2D Raman-mapped image based on the peak intensity ratio I 1618 / I 232 corresponding to each concentration. As the I 1618 /I 232 ratio increased, the color of the Raman image changed significantly from purple to red.…”

Section: Bd-tau Detection Of Plasma Based On the Mose 2 Sers Platformmentioning

confidence: 99%

See 1 more Smart Citation

Simple Plasma Test Based on a MoSe₂ SERS Platform for the Specific Diagnosis of Alzheimer’s Disease

Zhou

Zheng

et al. 2023

Chemical & Biomedical Imaging

View full text Add to dashboard Cite

As a significant Alzheimer’s disease (AD)-specific biomarker, the examination of brain-derived tau (BD-tau) is significant in terms of the diagnosis and differentiation of neurological disorders. In this research, sea urchin-like MoSe2 microspheres were synthesized by hydrothermal synthesis, revealing significant SERS activity, and the enhancement factor (EF) reached 1.44 × 107. The remarkable EF was mainly ascribed to the (i) charge transfer between MoSe2 and MB, (ii) MB molecule’s resonance effect, and (iii) molecular enrichment of porous structures. Through an aptamer-antibody sandwich method, we prepared a BD-tau SERS detection platform based on sea urchin-like MoSe2 microspheres. The liner range was 0.05–200.00 pM with a limit of detection (LOD) as low as 0.028 pM. Besides, the developed detection platform demonstrated excellent selectivity and enabled early diagnosis of AD patients. In general, the MoSe2 SERS detection platform can well detect the concentration of BD-tau in mouse plasma samples, showing great potential in specific recognition of AD among neurodegenerative diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Bd-tau Detection Of Plasma Based On the Mose 2 Sers Platformmentioning

confidence: 99%

Simple Plasma Test Based on a MoSe₂ SERS Platform for the Specific Diagnosis of Alzheimer’s Disease

Zhou

Zheng

et al. 2023

Chemical & Biomedical Imaging

View full text Add to dashboard Cite

show abstract

“…Immunoassay is based on specific antigen-antibody binding including western blot, ELISA, and immuno-magnetic reduction. 19 ELISA is one of the most important methods of detecting tau protein. Although it is used for tau protein detection via a simple operation, it is still time-consuming and requires advanced tools.…”

Section: Tau Protein Pathophysiologymentioning

confidence: 99%

Tau Protein Biosensors in the Diagnosis of Neurodegenerative Diseases

et al. 2022

View full text Add to dashboard Cite

Tau protein plays a crucial role in diagnosing neurodegenerative diseases. However, the assay employed to detect tau protein on a nanoscale is a great challenge for the early diagnosis of diseases. ELISA, western-blotting, and molecular-based methods such as PCR and Real-time PCR are the most widely used methods for detecting tau protein. Such methods are subject to certain limitations: the need for advanced equipment, low sensitivity, and specificity, to name a few. Accordingly, the necessity of discovering advanced and novel methods for monitoring tau protein becomes highlighted. Biosensors are one of the remarkable methods considered by researchers that can largely eliminate the problems and limitations associated with routine methods. The main objective of the present study was to review the latest biosensors developed to detect the tau protein. Further, the problems and limitations of routine diagnosis methods were discussed in detail.

show abstract

“…On the other hand, there is an urgent need for sensitive and rapid detection of disease marker proteins to recognize patients with diseases at the early stage. For example, Alzheimer’s disease (AD) is an unremitting progressive neurodegenerative disorder, which brings severe psychological and financial burden to the society. − Therefore, assay of tau proteins, an important biomarker for AD, has received more and more attention. However, the majority of the analytical methods are either time-consuming or insufficiently sensitive. − For instance, most of the assays may take hours or even days because of the complicated analytical processes.…”

mentioning

confidence: 99%

Polyvalent Biotinylated Aptamer Scaffold for Rapid and Sensitive Detection of Tau Proteins

et al. 2020

View full text Add to dashboard Cite

Biomimetic construction of artificial scaffolds has attracted increasing attention. However, the construction methods usually require redundant materials and procedures, which is inconvenient for further application. Herein, inspired by the polyvalent multifunctional structure in nature, we have designed a polyvalent biotinylated aptamer scaffold (PBAS) which can conduct analytical performance with high sensitivity and simplified procedures. To construct a PBAS, the aptamers are designed to hybridize with prepared linker probes to form polyvalent biotinylated scaffolds, which contain both multiple aptamers and signal labels. Therefore, multifunctional scaffolds can be constructed with high recognition and capture efficiency as well as significant signal amplification. Furthermore, the scaffold can be used for the assay of some disease marker proteins. By taking tau proteins as an example, the proposed aptasensor can exhibit excellent performance with a low detection limit of 153 pg mL–1 and a short assay time of 50 min, which is much better than most of the previous methods. By assays of tau proteins in both serum and artificial cerebro spinal fluid, the PBAS-based aptasensor can work well. Therefore, the scaffold may be expected to be a powerful analytical tool which may have wide applications in the detection of a variety of analytes.

show abstract

Progress in Analysis of Tau Protein

Cited by 7 publications

References 81 publications

Simple Plasma Test Based on a MoSe₂ SERS Platform for the Specific Diagnosis of Alzheimer’s Disease

Simple Plasma Test Based on a MoSe₂ SERS Platform for the Specific Diagnosis of Alzheimer’s Disease

Tau Protein Biosensors in the Diagnosis of Neurodegenerative Diseases

Polyvalent Biotinylated Aptamer Scaffold for Rapid and Sensitive Detection of Tau Proteins

Contact Info

Product

Resources

About

Progress in Analysis of Tau Protein

Cited by 7 publications

References 81 publications

Simple Plasma Test Based on a MoSe2 SERS Platform for the Specific Diagnosis of Alzheimer’s Disease

Simple Plasma Test Based on a MoSe2 SERS Platform for the Specific Diagnosis of Alzheimer’s Disease

Tau Protein Biosensors in the Diagnosis of Neurodegenerative Diseases

Polyvalent Biotinylated Aptamer Scaffold for Rapid and Sensitive Detection of Tau Proteins

Contact Info

Product

Resources

About

Simple Plasma Test Based on a MoSe₂ SERS Platform for the Specific Diagnosis of Alzheimer’s Disease

Simple Plasma Test Based on a MoSe₂ SERS Platform for the Specific Diagnosis of Alzheimer’s Disease